The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors

The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors

Background: Approximately 10%–30% of patients with Hodgkin's lymphoma (HL) experience relapse or refractory (R/R) disease after first-line standard therapy. Brentuximab vedotin (BV) and immune checkpoint inhibitors (ICIs) have important roles in the salvage treatment of R/R HL. However, subsequ...

Full description

Bibliographic Details
Main Authors: Ruizhi Zhao, Han Shao, Guiqing Shi, Yanyan Qiu, Tianlan Tang, Yuping Lin, Silin Chen, Cheng Huang, Siqin Liao, Jinhua Chen, Haiying Fu, Jianzhi Liu, Benhua Xu, Tingbo Liu, Yujing Zhang, Yong Yang
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Journal of the National Cancer Center
Subjects:
Radiotherapy
Hodgkin's lymphoma
Brentuximab vedotin
Immune checkpoint inhibitors
Refractory
Relapsed
Online Access:http://www.sciencedirect.com/science/article/pii/S2667005423000790

Internet

http://www.sciencedirect.com/science/article/pii/S2667005423000790

Similar Items